Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
Recent Progress
It is generally acknowledged that LacZ has two functional activities. It is capable of hydrolyzing lactose to galactose and glucose and catalyzing the intramolecular isomerization of lactose to allolactose(Fig. 1).
Fig. 1. Stereoviews of LacZ with allolactose, Bis-Tris, and l-ribose ligands. (RW Wheatley et al, 2013)
In 103 muscle cells of the nematode Caenorhabditis elegans, the product of an integrated transgene offers a convenient and cell-specific reporter of intracellular protein catabolism. The transgene is essentially a fusion of a 5'-region of the C. elegans unc-54 gene to the lacZ gene of Escherichia coli. The transgene encodes a 146-kDa fusion polypeptide that in turn forms active beta-galactosidase tetramers. In vivo, this particular protein is stable in well-fed animals, however, after removal of the food source, it is inactivated exponentially with an initial lag of 8 h. From the data collected, it can be concluded that degradation is paradoxically faster than inactivation. Moreover, several characteristic immune-reactive degradation intermediates are also found in active protein, part of which conjugated to ubiquitin. These findings, taken together, proposed that the initial proteolytic cleavages occur in the cytosol, highly likely through an ubiquitin-mediated pathway.
To thoroughly understand the cellular physiology and the regulation of the AOX1 promoter, also to quantitatively evaluate the benefits of a methanol/sorbitol co-feeding process in which the pAOX1-lacZ construct was used as a reporter gene, researchers performed a series of transient continuous cultures. The findings revealed quantitative insight into the co-feeding process, also provided data for the control of methanol/sorbitol co-feeding. Given the data collected, the investigators believed that the productivity of lacZ could be improved about 40% with the optimally mixed feed.
Based on G794A-β-galactosidase (a substituted enzyme) trapping the allolactose, researchers present structural data that maps the glucose site. Further investigation suggested that the glucose from the trapped allolactose is in the acceptor position. A loop covering the Ser-796 and Glu-797 closes over the active site. This loop seems important for the two functional activities of LacZ, since it helps shape the glucose binding site. More intriguingly, given the mobility of the loop, glucose binding becomes transient, thus allowing the release of some glucose. Further bioinformatics studies and genomic analyses indicated that the glucose binding site of LacZ played a crucial role in evolution of lac operon.
β-Propiolactone (BPL) and N -methyl- N ′-nitro- N -nitrosoguanidine (MNNG) are two direct alkylating agents. They are capable of inducing multiple genetic lesions and tumors in the rodent stomach. In order to determine the optimal sampling time and also to investigate the cause-effect relationship between DNA damage and gene mutations, researchers measured the kinetics of the induction of DNA damage and the induction of gene mutations. After a single oral administration of BPL or MNNG given at certain time, the lacZ mutant frequency was strongly enhanced at the highest doses and all sampling times. Only a small increase in lac Z mutant frequency was found at the lowest doses and both sampling times. These findings, taken together indicated the ability and complementarity of the SCGE and Muta64Mouse models to assess the genotoxicity of direct alkylating agents in the mouse gastric mucosa in vivo.
Through determination of the nucleotide sequence of the Escherichia coli/Aggregatibacter actinomycetemcomitans shuttle vector pYGK, researchers were allowed to design and construct a new shuttle cloning vector, pJT4, and promoterless lacZ transcriptional/translational fusion plasmids, pJT3 and pJT5. More specifically, plasmids pJT4 and pJT5 possess the origin of replication needed to maintain shuttle vector replication. moreover, to generate a scarless and markerless deletion mutations of genes in the oral pathogen A. actinomycetemcomitans, researchers also designed a new suicide vector pJT1. Plasmid pJT1 does not leave antibiotic markers or scars on the chromosome even after gene deletion, thus allow the researchers to combine several mutations in the same genetic background.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.